Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
The DOI matches its Crossref record, with a small difference in title or year; 30 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND Retatrutide, a glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonist, has demonstrated robust glucose and bodyweight reductions in participants with type 2 diabetes. This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide. METHODS This phase 2, double-blind, parallel-group, placebo-controlled, randomised controlled trial was done in 42 medical centres in the USA. Eligible participants were adults aged 18-75 years with type 2 diabetes, HbA1c of 7·0-10·5%, stable bodyweight, and BMI of 25-50 kg/m2. Eligible participants were randomly assigned in a 2:2:2:1:1:1:1:2 ratio to once-weekly subcutaneous placebo, dulaglutide 1·5 mg, or retatrutide 0·5 mg, 4 mg (2 mg initial dose), 4 mg (4 mg initial dose), 8 mg (2 mg initial dose), 8 mg (4 mg initial dose), or 12 mg. The prespecified primary substudy endpoint was percent change from baseline to week 36 in total fat mass, as measured by dual-energy X-ray absorptiometry (DXA). Regression methods with on-treatment data before study drug discontinuation from all randomly assigned participants with non-missing DXA scans were included in efficacy analysis. All participants who received at least one dose of study drug were included in the safety analysis population. The completed trial is registered with ClinicalTrials.gov, NCT04867785. FINDINGS Between May 13, 2021 and June 13, 2022, 534 participants were screened for inclus…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retatrutide appeared to induce lean mass loss in similar proportions to GLP-1RAs alone, whereas PTT-A has shown robust fat reduction without significant decrease in muscle mass, highlighting the potential of selective multi-agonists to preserve skeletal muscle during weight loss [66, 67].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [66]
In the citing paper
“Retatrutide appeared to induce lean mass loss in similar proportions to GLP-1RAs alone, whereas PTT-A has shown robust fat reduction without significant decrease in muscle mass, highlighting the potential of selective multi-agonists to preserve skeletal muscle during weight loss [66, 67].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [66]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Shuster, A., Patlas, M., Pinthus, J. H., & Mourtzakis, M. (2012) · The British Journal of Radiology · doi:10.1259/bjr/38447238 · Cited by 918
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationObesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Multiple Imputation for Nonresponse in Surveys.
Sugden, R. A., & Rubin, D. B. (1988) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2983027 · Cited by 702
Persistent metabolic adaptation 6 years after “The Biggest Loser” competition
Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., Chen, K. Y., Skarulis, M. C., Walter, M., Walter, P. J., et al. (2016) · Obesity · doi:10.1002/oby.21538 · Cited by 672
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Self-citationOlbers, T., Bj??rkman, S., Lindroos, A., Maleckas, A., L??nn, L., Sj??str??m, L., & L??nroth, H. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000218085.25902.f8 · Cited by 340
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Self-citation
Cited by
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“A sub-study of a phase 2 trial analyzed changes in body composition (using dual-energy X-ray absorptiometry) and revealed reductions in lean mass of up to 12.5% and reductions in fat mass of 26.1%, in patients with T2D treated with retatrutide (8 mg QW) over 36 weeks 87 .”
InfluentialMuscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
“Notwithstanding these methodological limitations and confounders, it is also important to point out that outside of two studies, 2,4 the majority of clinical studies with incretin-based treatments did not find a disproportionate contribution of LBM to weight loss but were remarkably close to the…”
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[162] However, there are reports indicating that some patients have developed relatively serious side effects such as kidney stones.”
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Metadata
- Authors
- Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Harris, Charles
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-08
- Volume
- 13
- Issue
- 8
- Pages
- 674-684
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4411966369
- Cited by
- 57
- References
- 32
- Citations by year
- 2026: 53 · 2025: 4
- FWCI
- 38.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- retatrutide, type 2 diabetes, body composition, fat mass, body weight, dulaglutide, GLP-1 receptor agonists, weight loss, dual-energy X-ray absorptiometry, dose-response relationship, insulin resistance, HbA1c, adverse events, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Body Composition, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Fatty Acids, Female, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Peptides, Recombinant Fusion Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(25)00092-0
- The paper
- Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00092-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.